Table 2 Evaluation and treatment of patients prior to icatibant administration

Medication history taken

23

NA

23 (100)

NA

1.00

Pertinent positive or negative recorded

12

ACEI

10 (83)

100

0.23

ARB

3 (25)

0.00*

NSAID

5 (42)

0.00*

Estrogen exposure

1 (8)

0.00*

Family history

1 (8)

0.00*

Allergies

11 (92)

0.50

Conventional medication administered before icatibant

15

Any diagnosis

NA

NA

  Antihistamines

9 (60)

  Glucocorticoid

11 (73)

  Epinephrine

7 (47)

  C1-INH

4 (27)

  FFP

5 (33)

HAE (n = 3)

  Antihistamines

0 (0)

  Glucocorticoid

0 (0)

  Epinephrine

0 (0)

  C1-INH

3 (20)

  FFP

0 (0)

Non-HAE (n = 12)

  Antihistamines

10 (67)

  Glucocorticoid

12 (80)

  Epinephrine

8 (53)

  C1-INH

1 (7)

  FFP

5 (33)

Treatment if signs of mast cell activation

2

Epinephrine

2 (100)

100

1.00

Antihistamines

2 (100)

1.00

Glucocorticoids

2 (100)

1.00

Treatment if no signs of mast cell activation

21

Epinephrine

6 (29)

0

0.01*

Antihistamines

8 (38)

0.00*

Glucocorticoids

9 (43)

0.00*

CBC before icatibant

23

Any diagnosis

17 (74)

100

0.01*

10

Prior HAE diagnosis

4 (40)

0.01*

13

No HAE diagnosis

13 (100)

1.00

Basic chemistry

23

Any diagnosis

12 (52)

100

0.00*

10

Prior HAE diagnosis

2 (20)

0.00*

13

No HAE diagnosis

10 (77)

0.11

C4 level

23

Any diagnosis

9 (38)

100

0.00*

10

Prior HAE diagnosis

4 (40)

0.01*

13

No HAE diagnosis

5 (38)

0.00*

C1-INH level

23

Any diagnosis

11 (48)

100

0.00*

10

Prior HAE diagnosis

5 (50)

0.02*

13

No HAE diagnosis

6 (46)

0.00*

C1-INH function

23

Any diagnosis

7 (30)

100

0.00*

10

Prior HAE diagnosis

4 (40)

0.01*

13

No HAE diagnosis

3 (23)

0.00*